Opinion|Videos|December 1, 2025
Other Key Data in Gastric/GEJ Cancer Presented at ESMO 2025
Author(s)Yelena Y. Janjigian, MD, Zev A. Wainberg, MD
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss other key gastric cancer data presented at the 2025 ESMO Congress.
Advertisement
Episodes in this series
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, highlight additional noteworthy gastric and GEJ cancer studies showcased at the 2025 ESMO Congress, including larger trials with potential practice-changing impact. They discuss emerging agents and novel combinations that may introduce new mechanisms of action or refine treatment sequencing, along with promising early-phase data that warrant continued attention as future therapeutic contenders. In particular, they delve into findings from the MATTERHORN trial that could bring perioperative immunotherapy to gastric/GEJ cancer management.
Advertisement
Related to this article
Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
iMMagine-1 vs CARTITUDE-1 MAIC Shows Comparable Efficacy, Improved Safety With Anito-Cel in Relapsed/Refractory Multiple Myeloma
3
Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma
4
Dr Kahl on Frontline Strategies for Avoiding Autologous Transplant in MCL
5